Several animal studies have shown that Branched-chain amino acids (BCAAs) may prevent acute liver injury, although its effects in humans are as yet undetermined. Thus the purpose of this study is to evaluate the impact of intravenous BCAAs infusion on liver profile post-liver surgery in the intensive care unit (ICU).

Microscopic colitis (MC) is characterized by non-bloody, watery diarrhea predominantly in elderly women. Known risk factors are smoking, medication with NSAIDs, PPIs or SSRIs, while data on hormonal factors is sparse. The aim of the present study was to investigate whether hormonal factors that disrupt the sex hormonal balance could have an impact on the disease course in MC.

Senescence is an irreversible cell cycle arrest -characterized by morphological alterations, genomic instability and secretome changes- that profoundly affects the tissue structure and function. Accumulating evidence indicates that senescence plays a relevant role in gastrointestinal pathologies: senescence contributes to salivary gland hypofunction, is instrumental in the development of oral sub-mucous fibrosis, drives age-dependent hepatic steatosis and regulates the clinical progression of steatotic liver disease. Senescence in the biliary tract develops in response to ischemic injury in biliary complications and is characteristic of biliary conditions such as biliary atresia, primary sclerosing cholangitis and primary biliary cirrhosis. Senescence also contributes to acute pancreatitis and plays a major role in the dysfunction of pancreatic beta cells. Moreover, senescence is a hallmark of a number of gastrointestinal conditions such as inflammatory bowel disease and colorectal cancer. These examples illustrate the widespread effect of cellular senescence in the gastrointestinal tract, not just as a consequence of the disease, but as a driver of pathology and a potential therapeutic target. In this review we describe the mechanisms, hallmarks and consequences of cellular senescence, as well as the therapeutic potential of senescence-targeting interventions. We aim to highlight the importance of understanding the molecular basis of senescence in gastroenterology, whilst connecting the worlds of research and clinical practice.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for glycemic control or weight management in patients with type 2 diabetes mellitus (T2DM) or overweight/obesity. However, there are concerns regarding their association with serious gastrointestinal adverse events though findings have been inconsistent.

Current diagnosis of celiac disease (CeD) is inaccurate in patients following a gluten-free diet (GFD). Blood-based diagnostics targeting gluten-specific T cells, like tetramer assays, are highly sensitive and specific but are impractical for clinical use. We evaluated the potential of a simple whole blood assay measuring interleukin-2 release (WBAIL-2) for detecting gluten-specific T cells to aid in CeD diagnosis.

Gastrointestinal (GI) clinicians are a critical touchpoint for individuals at risk for genetic and familial syndromes that increase risk of colorectal, gastric and pancreatic cancer. While advances in sequencing technology and reduced costs have made genetic testing more readily accessible to clinicians and even to patients through direct-to-consumer testing, uptake of genetic testing remains underutilized. This is a missed opportunity to identify patients and family members who could benefit from genetic testing to diagnose cancer susceptibility syndromes for which surveillance and preventive interventions exist. Barriers for integration of genetic testing in routine practice include lack of awareness about genetic conditions by patients and providers, concerns about genetic testing costs and implications for insurability, as well as challenges in implementing algorithms for risk assessment and coordinated care in complex medical systems. This review addresses current evidence and guidelines for cancer risk assessment, genetic testing and management to enable GI clinicians to identify and care for individuals with genetic cancer-predisposition syndromes in routine practice.

In a treat to target era, objective disease assessment in inflammatory bowel disease (IBD) has become increasingly important. For many years, endoscopy has been generally accepted as the gold standard for evaluating the bowel mucosa, additionally facilitating biopsy. However, non-invasive disease assessment is now increasingly demanded and cross-sectional imaging techniques as well as video capsule endoscopy have markedly improved. Emerging evidence demonstrates the added clinical value of transmural assessment both in Crohn's disease and ulcerative colitis, and cross-sectional imaging modalities are increasingly used in phenotyping and monitoring IBD patients. In the current review we propose potential algorithms to use non-invasive imaging in various clinical scenarios and for use in daily practice. The readers will come away with an understanding of what imaging they should consider for different clinical situations and the strengths and limitations of each modality. Future developments of non-invasive diagnostic strategies and areas in need of further research are highlighted.

There is limited data on inflammatory bowel disease advanced therapy sequences. Therefore, we examined real-world advanced therapy sequences to compare persistence, healthcare use and costs in first-line advanced therapy.

ZBTB10 is a member of the zinc finger and bric-a-brac/tramtrack/broad (ZBTB) domain-containing protein family, reported to be associated with tumorigenesis and progression. However, its specific roles in oncogenesis, prognosis, and immune infiltration in stomach adenocarcinoma (STAD) remain to be elucidated.